Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Ratio: 2016-2025

Historic Equity Ratio for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to 0.11.

  • Akebia Therapeutics' Equity Ratio rose 146.94% to 0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.11, marking a year-over-year increase of 146.94%. This contributed to the annual value of -0.22 for FY2024, which is 76.15% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Equity Ratio stood at 0.11, which was up 35.07% from 0.08 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Equity Ratio registered a high of 0.34 during Q1 2021, and its lowest value of -3.49 during Q3 2022.
  • For the 3-year period, Akebia Therapeutics' Equity Ratio averaged around -0.08, with its median value being -0.12 (2024).
  • As far as peak fluctuations go, Akebia Therapeutics' Equity Ratio plummeted by 1,633.08% in 2022, and later soared by 165.55% in 2025.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Equity Ratio stood at 0.14 in 2021, then tumbled by 89.49% to 0.01 in 2022, then slumped by 961.44% to -0.13 in 2023, then crashed by 76.15% to -0.22 in 2024, then surged by 146.94% to 0.11 in 2025.
  • Its Equity Ratio stands at 0.11 for Q3 2025, versus 0.08 for Q2 2025 and 0.08 for Q1 2025.